Interim Phase 1b/2 data on AU-011 presented by Carol Shields, M.D., at AAO 2017 show safety and preliminary efficacy at three months post-treatment.
Carol Shields, M.D., of the Wills Eye Hospital in Philadelphia, will present data from Aura's Phase 1b clinical safety study of AU-011 at AAO 2017.
Kaliki S and Shields C L
International Journal of Cancer
Kines R, Cerio R, Roberts J, Thomson C, de los Pinos E, Lowy D, Schiller J
National Institutes of Health